Skip Navigation

This Article
Right arrow Print PDF (3214K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (55)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Jaxel, C.
Right arrow Articles by Yves, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaxel, C.
Right arrow Articles by Yves, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1988, Vol. 16, No. 23 11157-11170
© 1988

ENZYMOLOGY

Topoisomerase I Interaction with SV4O DNA in the presence and absence of camptothecin

Christine Jaxel, Kurt W. Kohn and Pommier Yves*

Laboratory of Molecular Pharnmcology, Developmental Therapeutics Program, Division of Cancer Treatment, National Institutes of Health Bethesda, MD 20892, USA

*To whom reprint requests should be addressed at BLDG 37, RN 5A19. Phone: (301)-496-5944

Received August 23, 1988. Revised November 3, 1988. Accepted November 3, 1988.

Camptothecin is an antitumor drug, which is a specific inhibitor of eukaryotic topoisomerase I. Enzyme inhibition is related to the stabilization of cleavable complexes between topoisomerase I and DNA. The genomic and DNA sequence localization of L1210 topoisomerase I-mediated DNA breaks produced by camptothecin were determined in the SV4O genome. DNA cleavage was predominantly single-stranded and localized in selective regions of the DNA. A major cleavage site was found at nucleotide 4955 on the coding strand in the early transcription region. The DNA sequence was determined at prominent cleavage sites (nucleotides 127 and 199 in the two 72 bp repeats and nucleotide 4955). A DNA consensus sequence 5'-GATG-3' was found in SV4O DNA. Cleavage occured between the T and the G and topoisomerase I was linked to the 3'-DNA terminus at the T position. The sequence GATG is more frequent in the non transcribed strand of the early and late transcription of SV4O than in the transcribed strands. This finding is consistent with the role of topoiscrerase I in transcription.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
S. Antony, P. B. Arimondo, J.-S. Sun, and Y. Pommier
Position- and orientation-specific enhancement of topoisomerase I cleavage complexes by triplex DNA structures
Nucleic Acids Res., October 4, 2004; 32(17): 5163 - 5173.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Antony, M. Jayaraman, G. Laco, G. Kohlhagen, K. W. Kohn, M. Cushman, and Y. Pommier
Differential Induction of Topoisomerase I-DNA Cleavage Complexes by the Indenoisoquinoline MJ-III-65 (NSC 706744) and Camptothecin: Base Sequence Analysis and Activity against Camptothecin- Resistant Topoisomerases I
Cancer Res., November 1, 2003; 63(21): 7428 - 7435.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Pommier, G. Kohlhagen, P. Pourquier, J. M. Sayer, H. Kroth, and D. M. Jerina
Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages
PNAS, February 29, 2000; 97(5): 2040 - 2045.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.